Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Biosimilars Struggle to Gain U.S. Market Share

Despite numerous FDA approvals of biosimilars, they have not yet gained a significant stake in the U.S. marketplace, according to a recent analysis published in Forbes.

Read More »

Pfizer’s Avastin biosimilar wins FDA approval

The U.S. Food and Drug Administration approved Pfizer Inc.’s biosimilar to Roche Holding AG’s blockbuster cancer treatment Avastin.

Read More »

FDA Approves Amgen and Allergan’s Kanjinti

Amgen Inc. and Allergan plc announced that the U.S. FDA approved Kanjinti (trastuzumab-anns) for all approved cancer indications of the reference product Herceptin.

Read More »

New Subcutaneous Formulation of Celltrion Healthcare’s Biosimilar CT-P13 Shows Positive Results for Treatment of Rheumatoid Arthritis

Celltrion Healthcare presented new findings at the Annual European Congress of Rheumatology (EULAR 2019) from a two-part study investigating the pharmacokinetics, efficacy and overall safety of CT-P13 SC in patients with rheumatoid arthritis during the treatment period of one year.

Read More »

Annual Report 2019: State of the Bio Industry

This annual compilation reviews new developments, trends and outlooks in areas such as biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biosimulation.

Read More »

British Columbia to be first Canadian province to switch patients to biosimilars

The Canadian province of British Columbia said its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars.

Read More »

“Biosimilars & Breast Cancer” White Paper

Through consultation with physicians and patients, the Canadian Breast Cancer Network (CBCN) outlined five key recommendations for consideration when implementing biosimilars in oncology

Read More »

EVERSANA and OptimizeRx Partner to Deliver High Tech and High Touch Pharmaceutical Services

EVERSANA and OptimizeRx Corp. announced their partnership to modernize the patient experience and improve health outcomes by combining a real-time electronic health records (EHR) network with customized, wraparound patient support services.

Read More »

Novartis’ Sandoz strikes deal for biosimilar of Herceptin

Novartis AG’s Sandoz division struck a deal with Taiwan’s EirGenix Inc. to market a biosimilar version of Roche’s Herceptin that is in late-stage development to treat some cancer tumors.

Read More »

AbbVie’s Skyrizi drug to treat psoriasis wins U.S. approval

The U.S. FDA approved AbbVie Inc.’s Skyrizi as a treatment for plaque psoriasis at a time when the company’s blockbuster psoriasis medicine Humira faces patent pressures.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom